Myelodysplastic Syndromes (MDS)
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Introduction: Myelodysplastic Syndrome (MDS) represents a group of cancers characterized by abnormal blood cell formation and maturation, leading to various degrees of cytopenias and potential transformation to acute myeloid leukemia
Evolving therapies for lower-risk myelodysplastic syndromes
The development in the therapeutic landscape of myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik
Targeting TP53 Mutations in Myelodysplastic Syndromes
Mutations in TP53 are observed in ∼20% of patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-P
Surapol Issaragrisil, MD
Institution
Siriraj Hospital
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Veronica Dioverti, MD
Institution
Johns Hopkins University School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
M. Veronica Dioverti, M.D. is a Clinical Associate in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. She graduated from Universidad Nacional de Asuncion and completed her internship and residency training at Bridgeport Hospital-Yale University in Bridgeport, CT. She then pursued General and Transplant/Oncology Infectious Diseases fellowships at Mayo Clinic in Rochester, MN. Her primary clinical interest is caring for transplant, hematology/oncology malignancies and other immunocompromised patients. Her research has focused on optimizing the diagnosis of
Rena Buckstein, MD, FRCP
Institution
Odette Cancer Center - Sunnybrook Health Sciences Centre
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
About
Dr. Buckstein's research is clinical and focused on novel biological therapies for MDS and lymphomas. She is a clinician-investigator and interacts closely with the scientists of Sunnybrook Research Institute and elsewhere on collaborative projects
David Gómez Almaguer, MD
Institution
Gomez Almaguer Clinica de Hematologia
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Myelodysplastic Syndromes (MDS)